Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
作者： Athanasios Kotsakis , Vassilis Georgoulias
DOI: 10.1517/14656566.2010.498581
关键词:
摘要: Importance of the field: The management non-small-cell lung cancer (NSCLC) has undergone a paradigm shift in last decade, with survival advantage demonstrated by incorporation anti-epidermal growth factor receptor (EGFR) agents to standard treatment advanced/metastatic NSCLC.Areas covered this review: We review existing data regarding distinct anti-EGFR NSCLC and potential role investigated biomarkers clinical outcome.What reader will gain: Tyrosine kinase inhibitors have been used first-line, second-line more settings extremely good results subgroup patients. Cetuximab remains only monoclonal antibody show benefit when combined cytotoxic agent front-line setting. Anti-EGFR is associated dramatic patients, emphasizing importance customizing treatment. Several for their predic...
informahealthcare.com参考文章(189)
Carolyn I. Sartor, Biological modifiers as potential radiosensitizers: targeting the epidermal growth factor receptor family. Seminars in Oncology. ,vol. 27, pp. 15- 20 ,(2000)
Harlan W. Waksal, Role of an anti-epidermal growth factor receptor in treating cancer. Cancer and Metastasis Reviews. ,vol. 18, pp. 427- 436 ,(1999) , 10.1023/A:1006302101468
X.-D. Yang, A. Jakobovits, Ping Wang, C. G. Davis, X.-C. Jia, J. R. F. Corvalan, Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Research. ,vol. 59, pp. 1236- 1243 ,(1999)
Z Fan, Y Lu, X Wu, J Mendelsohn, Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. Journal of Biological Chemistry. ,vol. 269, pp. 27595- 27602 ,(1994) , 10.1016/S0021-9258(18)47026-3
Hideo Masui, Takamasa Moroyama, John Mendelsohn, Mechanism of Antitumor Activity in Mice for Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies with Different Isotypes Cancer Research. ,vol. 46, pp. 5592- 5598 ,(1986)
Zhen Fan, Hideo Masui, John Mendelsohn, Jose Baselga, Antitumor Effect of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies plus cis-Diamminedichloroplatinum on Well Established A431 Cell Xenografts Cancer Research. ,vol. 53, pp. 4637- 4642 ,(1993)
Holly M. Martinson, John H. Sampson, Gary E. Archer, Gregory J. Riggins, Chad A. Glazer, Anita Lal, Henry S. Friedman, Mutant Epidermal Growth Factor Receptor Up-Regulates Molecular Effectors of Tumor Invasion Cancer Research. ,vol. 62, pp. 3335- 3339 ,(2002)
Brian Fendly, Mien Chie Hung, Robert S. Kerbel, Alicia M. Viloria Petit, Patricia Rockwell, Neil Goldstein, Janusz Rak, Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. American Journal of Pathology. ,vol. 151, pp. 1523- 1530 ,(1997)
W.K. (Bill) Evans, Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer Cancer Treatment Reviews. ,vol. 30, pp. 655- 659 ,(2004) , 10.1016/J.CTRV.2004.08.002
Frank V. Fossella, Russell DeVore, Ronald N. Kerr, Jeffrey Crawford, Ronald R. Natale, Frank Dunphy, Leonard Kalman, Vincent Miller, Jin Soo Lee, Melvin Moore, David Gandara, Daniel Karp, Everett Vokes, Mark Kris, Yong Kim, Francis Gamza, Luz Hammershaimb, , Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Journal of Clinical Oncology. ,vol. 18, pp. 2354- 2362 ,(2000) , 10.1200/JCO.2000.18.12.2354